Novartis AG's Fiscal Year is From January To December - All Figures are in Thousands.
The item "Working-Capital-Turnover" stands at -0.015 Thousand as of 09/30/2025.
As of the end of Novartis AG's third quarter, the item "Working Capital Turnover" stands at -0.015 Thousand. This represents an increase of 44.83 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -0.0961 Thousand compared to the value the year prior.
The Serie's long term average value is 0.107 Thousand. It's latest available value, on 09/30/2025, is -0.122 Thousand lower, compared to it's long term average value.
The Serie's change from it's minimum value, on 12/31/2024, to it's latest available value, on 09/30/2025, is +0.3209 Thousand.
The Serie's change from it's maximum value, on 03/31/2024, to it's latest available value, on 09/30/2025, is -1.91 Thousand.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Working Capital Turnover | 905,699,262,464.00 |
![]() | Johnson & Johnson - Working Capital Turnover | 486,508,953,600.00 |
![]() | AbbVie Inc - Working Capital Turnover | 399,570,305,024.00 |
![]() | Roche Holding AG - Working Capital Turnover | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Working Capital Turnover | 280,205,508,085.11 |